Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

The New England Journal of Medicine
L K KvolsR G Hahn

Abstract

We studied the effects of a long-acting analogue of somatostatin (SMS 201-995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome. This drug was self-administered by subcutaneous injection at a dose of 150 micrograms three times daily. Flushing and diarrhea associated with the syndrome were promptly relieved in 22 patients. All 25 patients had an elevated 24-hour urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) (mean, 265 mg per 24 hours; range, 14 to 1079), which served as an objective indicator of disease activity. Eighteen of the 25 patients (72 percent) had a decrease of 50 percent or more in their urinary 5-HIAA levels, as compared with the pretreatment values. The median duration of this biochemical response was more than 12 months (range, 1 to greater than 18). Since no serious toxicity was observed, we conclude that SMS 201-995 may be appropriate for use as early therapy in patients with symptoms due to the carcinoid syndrome who have not responded to simpler measures.

References

Nov 9, 1978·The New England Journal of Medicine·J C FrölichD Rabinowitz
Dec 15, 1983·The New England Journal of Medicine·S Reichlin
Nov 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C G Moertel

❮ Previous
Next ❯

Citations

Apr 30, 1999·The Prostate·P A Abrahamsson
May 18, 1999·International Journal of Cancer. Journal International Du Cancer·G D SlooterC H van Eijck
Oct 12, 2000·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·J MarencoN Pandian
Oct 18, 2002·Biopolymers·Sylvie Froidevaux, Alex N Eberle
Mar 1, 1995·Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·J K RamageR Williams
Sep 1, 1993·Seminars in Surgical Oncology·M J Demeure
Jan 1, 1990·Cardiovascular Drugs and Therapy·J I Robertson
May 1, 1994·Abdominal Imaging·A VillanuevaP Puig
Jan 1, 1995·World Journal of Surgery·I IhseS Tibblin
Mar 1, 1989·Digestive Diseases and Sciences·A Vinik, A R Moattari
May 1, 1990·World Journal of Surgery·C MakridisG Akerström
Feb 26, 1991·Klinische Wochenschrift·E KornelyF A Horster
Apr 1, 1990·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·K Monteith, O P Roaseg
Oct 1, 1990·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·J T WatsonM J Ali
May 27, 2005·The International Journal of Cardiovascular Imaging·Servet Tatli, Martin J Lipton
Sep 27, 2006·Pituitary·Eva Tiensuu Janson
Jun 21, 2002·Current Treatment Options in Oncology·Robin P Boushey, Alan P B Dackiw
Aug 19, 2005·Current Treatment Options in Oncology·Matthew Kulke
Dec 18, 2007·Current Treatment Options in Oncology·Peter J MazzagliaAllan E Siperstein
Mar 26, 2011·Current Treatment Options in Oncology·Jennifer A Chan, Matthew H Kulke
Jul 31, 2013·Current Treatment Options in Oncology·Jonathan Strosberg
Apr 14, 2007·Current Oncology Reports·Matthew H Kulke
Apr 2, 2009·Current Oncology Reports·Jennifer A Chan, Matthew H Kulke
Jan 29, 2008·Current Treatment Options in Cardiovascular Medicine·Alain M BernheimPatricia A Pellikka
Mar 30, 2007·Current Treatment Options in Gastroenterology·Wei Hou, Mitchell L Schubert
Jul 10, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Enrique GrandeAlfredo Carrato
Jan 18, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Wolfgang FiebigerGerhard Hamilton
Mar 5, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Catharina M KorseBabs G Taal
Jan 1, 1989·Pharmacology & Therapeutics·D WynickS R Bloom
Feb 1, 1995·Journal of the American College of Cardiology·H M ConnollyL K Kvols
Feb 1, 1992·Comparative Biochemistry and Physiology. C, Comparative Pharmacology and Toxicology·M B Hansen
Dec 20, 1990·The Journal of Steroid Biochemistry and Molecular Biology·S W LambertsE P Krenning
Sep 1, 1992·The Journal of Steroid Biochemistry and Molecular Biology·S W LambertsE P Krenning
Jan 1, 1995·Critical Reviews in Oncology/hematology·S Cascinu
Apr 14, 2004·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·P TomassettiR Corinaldesi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.